Skip to main content
Download PDF

Volume 14 Supplement 1

State of the Art 2016: Research and Review from the 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis

MicroRNA in atherothromobosis: is it useful as a disease marker?

Thrombosis Journal volume 14, Article number: 21 (2016) Cite this article

Abstract

Atherosclerosis is one of the major causes of death. Data from animal experiments suggest that atherosclerosis involves an inflammatory process of the vascular wall under hyperlipidemia. Atherothrombosis can become a serious complication of atherosclerosis leading to acute cardiovascular events such as myocardial infarction and stroke. Clinical applications to use this knowledge remain scarce. The plasma levels of vascular endothelium-enriched microRNA (miRNAs) in patients with atherosclerotic vascular disease could serve as a disease marker. In our laboratory vascular endothelium-enriched miRNA (miR-126) level was analyzed using quantitative RT polymerase chain reaction analysis (qRT-PCR) in plasma from patients with suspected coronary artery disease (CAD) according to the chest symptom or findings of electrocardiogram, or middle-aged male smokers. Endothelial function for peripheral small vessels was assessed using End-PAT 2000 and expressed as reactive hyperemia peripheral arterial tonometry (RH-PAT) index. In patients with suspected CAD miR-126 was not significantly changed in CAD patients. However, miR-126 was decreased in CAD patients who also have high levels of low-density lipoprotein (LDL) cholesterol. Interestingly, miR-126 was increased when LDL cholesterol was high in patients who did not have evident CAD on coronary angiography even though they have risk factors for CAD. In smokers serum cotinine levels were inversely correlated with endothelial function expressed as RH-PAT index and positively correlated with levels of metabolic parameters such as non-high-density lipoprotein (HDL) cholesterol and insulin resistance. More than half of the smokers could not completely attain smoking cessation and, thus, the RH-PAT index was not improved 8 weeks after the instruction of smoking cessation. However, changes in the RH-PAT index showed a significant correlation with those in systolic blood pressure. In smokers who completely attained smoking cessation, both RH-PAT index and plasma miR-126 values were increased. Thus, among patients with suspected CAD or subjects with coronary risk factors plasma levels of endothelium-enriched circulating miR-126 could be substantially altered. The results suggest a potential usefulness of miR-126 as a sensitive biomarker in assessing endothelial damage. Measurement of microRNA may serve as a useful tool for laboratory assays to determine high-risk patients for atherothromobotic vascular diseases.

Background

Coronary artery disease (CAD) is both a leading cause of death and an important health threat in Asian countries as well as in European countries. Markers for CAD in circulation have been sought and identified. However, only a few markers have important clinical implications. Disease biomarkers that can appropriately evaluate the risks for CAD and the early processes of atherosclerosis are desirable. Circulating microRNAs (miRNAs) could be useful candidates as disease biomarkers including cancer. MiRNAs are a class of 20-25 nt single-stranded noncoding RNAs. MiRNAs regulate cellular functions through modulating mRNA degradation and repress translation of mRNAs. MiRNAs regulate the gene expression regarding cell growth, proliferation and apoptosis. MiRNAs are found not only in tissues, but also in body fluids including plasma. Circulating miRNAs remain in stable forms and they are resistant to endogenous RNase. Therefore, the signatures of miRNA in circulation can be useful in diagnosis, therapeutic efficacy and prognosis.

Review

Use of microRNA for biomedical research in thrombosis

Use of microRNA for biomedical research in thrombosis and hemostasis has provided substantial useful information. Matsui et al. evaluated a modified lentiviral delivery strategy [1]. By incorporating miRNA target sequences they succeeded in facilitated transgene expression in liver and prevented off-target expression in hematopoietic cells. This system effectively restricted transgene expression of coagulation factor VIII (FVIII) to the liver. Level of FVIII in plasma was increased to 9 % of normal level in the hemophilia A mice. Thrombin is thrombogenic and mediates inflammation. Thrombin induces activation and dysfunction of endothelial cells through NF-kB and contributes to formation of arterial thrombus. MiR-181b possesses anti-inflammatory actions and inhibits downstream NF-kB signaling in response to TNF-α. MiR-181b also inhibits upstream NF-kB signaling induced by thrombin [2].

Dyslipidemia and microRNA

We measured circulating miRNA in CAD patients. Significant CAD was confirmed by angiography. MiRNA was also measured in patients without CAD [3]. This study was approved by our institutional ethical committee. Informed consent was obtained from all participants. Dysfunction of endothelium is implicated in early processes of atherosclerosis and thrombosis. Therefore, vascular endothelium-enriched miRNA (miR-126) that can potentially regulate angiogenesis was selected and measured. CAD patients who showed higher levels of myocardial stress marker, brain natriuretic peptide. Their average New York Heart Association class, an index of heart failure, was also higher. The prevalence of hypertension and diabetes were similar between the 2 groups. Patients without CAD showed lower prevalence of dyslipidemia. The lipid profiles were not significantly different between the 2 groups due to anti-hyperlipidemic drugs. Use of aspirin, α- blockers, angiotensin converting enzyme inhibition/angiotensin receptor blockers, statin, long-acting nitrates, insulin, and sulfonyl urea were less frequent in patients without significant CAD. Use of calcium channel blocker was not significantly different between the 2 groups. The levels of miRNA in circulation are relatively low. Thus, approach using microarray may not be sensitive enough to identify miRNAs that can serve as disease biomarkers. Therefore, quantitative RT polymerase chain reaction (qRT-PCR) analysis was utilized on RNA isolated from plasma. There are several plasma miRNAs that were previously reported to have altered levels in type 2 diabetes. We evaluated the candidate miRNAs. The analysis revealed that plasma miR-126 level of patients with CAD was comparable to the level of patients without CAD. This result indicated that miR-126 was not a specific marker for CAD. We noticed that there had been no report that level of miR-126 was influenced by low-density lipoprotein (LDL) cholesterol. The level of miR-126 was significantly decreased in CAD patients who also showed high LDL cholesterol level. The miR-126 level was increased in patients who had risk factors for CAD and high level of LDL cholesterol but did not have CAD. Taken together, our results suggested an association between dysregulated plasma miR-126 and elevated levels of LDL cholesterol in patients who have CAD.

Smoking, endothelial function and microRNA

We also determined microRNA in middle-age male smokers [4]. Serum cotinine levels, a metabolite marker of nicotine, were inversely correlated with endothelial function expressed as reactive hyperemia peripheral arterial tonometry (RH-PAT) index and high-density lipoprotein (HDL)-cholesterol level, and positively correlated with levels of non-HDL-cholesterol and homeostasis model-insulin resistance (HOMA-IR). The smokers were encouraged to stop smoking. The RH-PAT index was not changed after 8 weeks in all subjects, because only 13 subjects could attain smoking cessation, and PH-PAT did not improve in 17 subjects who could not attain smoking cessation. However, relative percent change of systolic blood pressure was significantly correlated with relative percent change of RH-PAT index. Furthermore, subjects with decreased systolic blood pressure exhibited significantly improved the RH-PAT index. Next, smokers who completely attained smoking cessation were analyzed separately. They indicated increased RH-PAT ratio and plasma miR-126 after 8 weeks of smoking cessation. However, RH-PAT index and expression levels of miR-126 did not show significant difference between subjects who completely attained 8 weeks smoking cessation and subjects who could not attain smoking cessation. These results suggested an association between dysregulated plasma miR-126 level and vascular endothelial damage in middle-age male smokers and favorable effect of smoking cessation on recovery of endothelial function and increase in miR-126 levels.

Platelets and microRNA for development of anti-thrombotic drugs

Bray et al. investigated the platelet transcriptome in black and white healthy subjects [5]. Platelet aggregation mediated through PAR4 thrombin receptor was greater in black subjects. Platelets from black subjects expressed lower levels of miR-376c. Lower miR-376c contributed to the higher expression of phosphatidylcholine transfer protein involved in platelet activation through thrombin. These results may imply that a genomic contribution to platelet function may differ by race. This difference may partly explain the lower survival of blacks as compared to whites after myocardial infarction due to coronary atherothrombosis. In the development of agents against thrombosis, one has to consider the effects of race.

Conclusions

MiRNAs emerged as new biomarkers useful for diagnosis and evaluation of pathophysiology of several atherothrombotic diseases. Standardization in samples, sample processing and storage need care in the laboratory. Technical protocols may become essential for the accurate assessment of miRNAs as biomarkers.

Abbreviations

CAD:

Coronary artery disease

FVIII:

Coagulation factor VIII

HDL:

High-density-lipoprotein

HOMA-IR:

Homeostasis model-insulin resistance

LDL:

Low-density-lipoprotein

miRNA:

MicroRNA

RH-PAT:

Reactive hyperemia peripheral arterial tonometry

References

  1. 1.

    Matsui H, Hegadorn C, Ozelo M, Burnett E, Tuttle A, Labelle A, McCray Jr PB, Naldini L, Brown B, Hough C, Lillicrap D. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. Mol Ther. 2011;19:723–30.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Lin J, He S, Sun X, Franck G, Deng Y, Yang D, Haemmig S, Wara AK, Icli B, Li D, Feinberg MW. MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10. FASEB J. 2016. [Epub ahead of print].

  3. 3.

    Sun X, Zhang M, Sanagawa A, Mori C, Ito S, Iwaki S, Satoh H, Fujii S. Expression of circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol. Thromb J. 2012;10:16.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Sugiura T, Dohi Y, Yamashita S, Iwaki S, Ito S, Sanagawa A, Ohte N, Fujii S. Circulating level of microRNA-126 may be a potential biomarker for recovery from smoking-related vascular damage in middle-aged habitual smokers. Int J Cardiol. 2015;7:83–7.

    Google Scholar 

  5. 5.

    Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Kong X, Nagalla S, Mohandas N, Cohen DE, Dong JF, Shaw C, Bray PF. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med. 2013;19:1609–16.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Ms. Noriko Saito for her secretarial assistance.

Declaration

Publication fees for this article have been funded by APSTH 2016.

This article has been published as part of Thrombosis Journal Volume 14 Supplement 1, 2016. The full contents of the supplement are available at https://thrombosisjournal.biomedcentral.com/articles/supplements/volume-14-supplement-1.

Availability of data and materials

Not applicable.

Authors’ contributions

SF, TS, YD and NO equally contributed to the conception and the design of the article. All authors have read and approved the manuscript in its final form to be submitted.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was approved by the institutional ethical committee and informed consent was obtained from all participants.

Author information

Affiliations

  1. Department of Laboratory Medicine, Asahikawa Medical University, Midorigaokahigashi 2-1-1-1, Asahikawa, 078-8510, Hokkaido, Japan

    Satoshi Fujii

  2. Medical Laboratory and Blood Center, Asahikawa Medical University Hospital, Asahikawa, Japan

    Satoshi Fujii

  3. Department of Cardio-Renal Medicine and Hypertension, Nagoya City University, Nagoya, Japan

    Tomonori Sugiura, Yasuaki Dohi & Nobuyuki Ohte

Authors
  1. Satoshi Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomonori Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuaki Dohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuyuki Ohte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Fujii.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fujii, S., Sugiura, T., Dohi, Y. et al. MicroRNA in atherothromobosis: is it useful as a disease marker?. Thrombosis J 14, 21 (2016). https://doi.org/10.1186/s12959-016-0112-2

Download citation

Keywords

  • Coronary artery disease
  • Plasma microRNA
  • LDL cholesterol
  • Smoking
  • Endothelium

Thrombosis Journal

ISSN: 1477-9560

Contact us